跳至主要内容
临床试验/NCT01756976
NCT01756976已完成不适用

Clinical Evaluation of the OrthoPAT Advance System

Haemonetics Corporation1 个研究点 分布在 1 个国家目标入组 84 人开始时间: 2012年12月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
84
试验地点
1
主要终点
Washed RBC Hematocrit

研究概览

简要总结

This study is intended to provide additional performance data of the OrthoPAT Advance in routine orthopedic surgery.

详细描述

The OrthoPAT Advance system is being developed by Haemonetics to change the user interface, especially for adding calculations for Estimating Blood Loss- (EBL). The OrthoPAT® serves as the predicate device. The following items will be changed in the OrthoPAT Advance system compared to OrthoPAT:

  • Software & User Interface - ability to enter irrigant and anti-coagulant volumes and allow Estimated Blood Loss (EBL) calculation to be made by OrthoPAT Advance.

  • Hardware -

  • Redesign of reservoir and filter to process blood earlier by reducing hold-up volume and improve fluid visualization in reservoir.

  • Extended battery life.

It is not intended to validate the major changes in the OrthoPAT Advance device (reservoir / filter and EBL), which will be conducted as lab based tests. The correct functioning of the reservoir / filter and EBL changes will be confirmed in the clinical setting in this study. However the most rigorous challenge to the filter will be by presenting the worst case media and this can only be controlled in the laboratory.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female over the age of 18 years
  • Subject is scheduled for a total knee/hip replacement/ revision or a hysterectomy.
  • Subjects determined eligible per site standard of care for use of intra- and post-operative use of cell salvage device

排除标准

  • For subjects where product is transfused
  • Subject is undergoing a trauma procedure where there is a possibility of contamination from an open wound.
  • Patient is diagnosed with sepsis.
  • Patient is diagnosed with sickle-cell anemia.
  • Malignant cells may be mixed with blood salvaged from the surgical field.
  • Prostatic or amniotic fluid is mixed with blood salvaged from the surgical field.
  • Blood salvaged from the surgical field may be contaminated from an active infection at wound/drain site.
  • Blood salvaged from the surgical field contains topical hemostatic agents, anti-bacterial agents, or wound irrigants not intended for parenteral use.
  • For all subjects:
  • Subject is undergoing a procedure which involves high, rapid blood loss such as liver transplants, certain cardiovascular procedures, and trauma procedures where blood loss is high (per Investigators judgment).
  • Any procedure terminated prior to completion by subject request, operator decision or error, or device error.
  • Any subject with which at least 200mL of filtered blood or 1 full disc is not available for processing and data collection within the study.

结局指标

主要结局

Washed RBC Hematocrit

时间窗: < 4 hours

The Hematocrit of the RBC shall be \> 50%.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Clinical Evaluation of the OrthoPAT Advance System | 临床试验